Microorganisms have always been a crucial part of the human environment.
Human beings have evolved with their microbiome, leading to profound effects on their immune system. In a similar way microorganisms have evolved multiple mechanisms to ensure their survival in man, allowing them to flourish without detrimental effects on their human host.
An example of one these microorganisms is Mycobacterium tuberculosis (mTB), which has evolved to produce specific proteins that demonstrate immuno-modulatory effects, dampening down the body’s immune response to ensure the bacteria can survive for decades within the human lung.
These proteins and derived peptides form the basis for Peptinnovate’s drug discovery and development strategy.
The original key observations and fundamental research came about through a collaboration between two leading British universities: King’s College, London and St George’s University, London.
Peptinnovate has identified and optimised proprietary molecules derived from mTB that have potential disease modifying activities. PIN201104, our lead clinical candidate, is a low molecular weight peptide and was identified by phenotypic drug discovery as having similar activities to the parent mTB protein. PIN201104 entered phase 1 clinical development in January 2017 as a first in class, disease modifier of asthma and other inflammatory diseases.
New molecules are currently in lead optimisation and will target additional immuno-inflammatory conditions.
|Hit to Lead||Lead optimisation||Preclinical development||Phase 1||Phase 2|
|PIN201104 Multiple indications|